Exceptional Survival with Lorlatinib in ALK-Rearranged Lung Cancer: A Case Report
Katarzyna Szklener, Karolina Nieoczym, Katarzyna Niedziela, Łukasz Światłowski, Sławomir Mańdziuk
Abstract
Genetic alterations in the ALK gene occur in approximately 3-5% of cases of non-squamous non-small cell lung cancer (NSCLC). These rearrangements are critical in determining how cancer cells respond to treatment with ALK inhibitors. However, over time, some patients may develop resistance, leading to disease progression. In such cases, performing genetic analysis is crucial to detect new mutations that could be driving resistance, enabling healthcare providers to select the most appropriate next
Topics & Concepts
Lung cancerMedicineCancer researchInternal medicineLung Cancer Treatments and MutationsCancer Genomics and DiagnosticsCholangiocarcinoma and Gallbladder Cancer Studies